Wave Life Sciences Ltd.

NASDAQ:WVE

Biotechnology

Healthcare
$2.77 +1.63%

+$0.10 today

Market cap
$546.32M
Beta
-1.33
P/E (TTM)
-6.6
EPS (TTM)
-$0.92
52W Low $5.02High $21.73

Volume 2.21M

Average 4.86M

WVE Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Wave Life Sciences Ltd.NASDAQ: WVE

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures growth accelerates

Q1 FY2026 capital expenditures of $438K (cash outflow) rose 165.5% year over year, ahead of the +43.1% change in trailing-twelve-month capital expenditures. Over 3 fiscal years it compounded at -19.2% a year.

Context

  • Capital expenditures amounted to 1.7% of revenue in FY2025, up 0.8 pp from a year earlier.
  • Capital expenditures grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +165.5% holds above the trailing-twelve-month pace of +43.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$438K-4476.1% QoQ
Last fiscal yearDec 2025
-$718K-23.5% YoY
LTMMar 2026
-$981.99K+43.1% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+165.5%——
1 year-23.5%——
3-year CAGR-19.2%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(718K) USD
Year-over-year change
+23.5%

Capital Expenditures vs competitors

How WVE compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +43.1% is the 4th highest of 10, against a peer median of +5.0%.
  • Capital expenditures amounts to 1.4% of revenue for WVE, versus a peer median of 2.7%.
WVE Competitors
Capital Expenditures for WVE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$91.95M USD+151.6%-6.6%1.9%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$71.85M USD+29.1%+36.8%7.5%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$69.14M USD-54.0%+46.8%3.2%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$12M USD-47.1%-59.2%2.7%
WVEWave Life Sciences Ltd.LTM Mar 2026$981.99K USD+43.1%-19.2%1.4%
PRQRProQR Therapeutics N.V.LTM Mar 2026€955.79K EUR+5.0%+11.4%7.1%
STOKStoke Therapeutics, Inc.LTM Mar 2026$871K USD+153.9%-44.7%2.7%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$473K USD-88.2%-53.7%0.7%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$318.66K USD-41.5%-69.0%0.7%
SLNSilence Therapeutics plcLTM Mar 2026$106K USD—-53.4%11.5%
BNTCBenitec Biopharma Inc.LTM Mar 2026$27.51K USD+48.2%+11.5%—
Peer median (excluding WVE) —+5.0%-25.7%2.7%

Competitors are the stored peer set for WVE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(122.25M)(161.82M)(57.51M)(97.01M)(204.38M)
Depreciation & Amortization9.84M10.11M9.21M8.66M8.85M
Deferred Income Tax(12.64M)0000
Stock-Based Compensation16.41M17.19M9.8M13.14M0
Change in Working Capital7.01M6.72M19.08M(75.82M)(16.94M)
Accounts Receivables30M0(21.09M)19.66M146K
Inventory2.04M0000
Accounts Payables(6.57M)9.35M(3.76M)3.42M(561K)
Other Working Capital(18.46M)(2.63M)43.93M(98.91M)(16.53M)
Other Non-Cash Items12.64M12K0024.97M
Operating Cash Flow(88.99M)(127.78M)(19.43M)(151.03M)(187.49M)
Capital Expenditures(560K)(1.36M)(1.12M)(938K)(718K)
Acquisitions (Net)00000
Purchases of Investments0(75.04M)000
Sales of Investments075.04M000
Other Investing Activities0106K000
Investing Cash Flow(560K)(1.26M)(1.12M)(938K)(718K)
Debt Repayment00000
Common Stock Issued54.97M52.33M131.28M236.18M488.24M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities858K14.86M1.26M17.71M0
Financing Cash Flow55.83M67.19M132.53M253.89M488.24M
Effect of Forex Changes(208K)(210K)(95K)(138K)12K
Net Change in Cash(33.93M)(62.06M)111.89M101.79M300.04M
Free Cash Flow(89.55M)(129.14M)(20.55M)(151.96M)(187.49M)

Wave Life Sciences Ltd.

NASDAQ:WVE

Intrinsic Alpha fair value

Locked

Current Price

$2.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.